Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
The overall survival (OS) has improved significantly in multiple myeloma (MM) over the last decade with the use of proteasome inhibitor and immunomodulatory drug-based combinations, followed by high-dose melphalan and autologous hematopoietic stem cell transplantation (auto-HSCT) and subsequent maintenance therapies in eligible newly diagnosed patients. However, clinical trials using auto-HSCT followed by lenalidomide maintenance have shown an increased risk of second primary malignancies (SPM), including second hematological malignancies (SHM). We evaluated the impact of SPM and SHM on progression-free survival (PFS) and OS in patients with MM after auto-HSCT using CIBMTR registry data. Adult patients with MM who underwent first auto-HSCT in the United States with melphalan conditioning regimen from 2011 to 2018 and received maintenance therapy were included (n = 3948). At a median follow-up of 37 months, 175 (4%) patients developed SPM, including 112 (64%) solid, 36 (20%) myeloid, 24 (14%) SHM, not otherwise specified, and 3 (2%) lymphoid malignancies. Multivariate analysis demonstrated that SPM and SHM were associated with an inferior PFS (hazard ratio [HR] 2.62, P < .001 and HR 5.01, P < .001, respectively) and OS (HR 3.85, P < .001 and HR 8.13, P < .001, respectively). In patients who developed SPM and SHM, MM remained the most frequent primary cause of death (42% vs 30% and 53% vs 18%, respectively). We conclude the development of SPM and SHM leads to a poor survival in patients with MM and is an important survivorship challenge. Given the median survival for MM continues to improve, continued vigilance is needed to assess the risks of SPM and SHM with maintenance therapy post-auto-HSCT.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10275699 | PMC |
| http://dx.doi.org/10.1182/bloodadvances.2022009138 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Clinical validation of an AI-based pathology tool for scoring of metabolic dysfunction-associated steatohepatitis.
Nat Med
January 2025
PathAI, Inc., Boston, MA, USA.
Article Synopsis
- Metabolic dysfunction-associated steatohepatitis (MASH) is a serious liver condition with limited treatment options and relies on manual biopsies for assessment, which often shows high variability among readers.
- A new artificial intelligence (AI) system, AIM-MASH, has been developed and validated across multiple sites to assist pathologists in scoring liver biopsies related to MASH, showing high reliability and consistency compared to traditional methods.
- AIM-MASH significantly improved the accuracy of assessing key factors like inflammation and MASH resolution when used by expert pathologists, suggesting it can reduce variability and enhance the evaluation of new treatments in MASH clinical trials.
Article Synopsis
- Overall survival rates for multiple myeloma have greatly improved due to advanced treatments like proteasome inhibitors and autologous stem cell transplants.
- However, there's an increased risk of developing second primary malignancies (SPM) and second hematological malignancies (SHM) after these treatments, affecting patients' post-transplant health.
- A study showed that patients who developed SPM and SHM had significantly lower progression-free survival (PFS) and overall survival (OS), highlighting the need for ongoing monitoring of these risks in survivorship care.
Chronic lymphocytic leukaemia (CLL) is invariably accompanied by some degree of immune failure, and CLL patients have a high rate of second primary malignancy (SPM) compared to the general population. We comprehensively documented the incidence of all forms of SPM including skin cancer (SC), solid organ malignancy (SOM), second haematological malignancy (SHM) and separately Richter's syndrome (RS) across all therapy eras. Among the 517 CLL/small lymphocytic lymphoma (SLL) patients, the overall incidence of SPMs with competing risks was SC 31.
View Article and Find Full Text PDFConfirmed disability progression as a marker of permanent disability in multiple sclerosis.
Eur J Neurol
August 2022
CORe, Department of Medicine, University of Melbourne, Melbourne, Australia.
Article Synopsis
- This study looks at how to predict long-term disability in people with multiple sclerosis (MS) after they show signs of worsening over six months.
- Researchers checked data from thousands of patients to figure out who is more likely to have lasting problems.
- They found that things like age, sex, and how MS affects the person can help tell if someone will continue to get worse, which can help doctors in future treatments.
Second primary malignancies induced by radioactive iodine treatment of differentiated thyroid carcinoma - a critical review and evaluation of the existing evidence.
Eur J Nucl Med Mol Imaging
July 2022
Department of Nuclear Medicine, University Hospital Marburg, Marburg, Germany.
Purpose: Concern is growing about long-term side effects of differentiated thyroid cancer treatment, most notably radioactive iodine (RAI) therapy. However, published studies on the subject have had heterogeneous cohorts and conflicting results. This review seeks to provide an updated evaluation of published evidence, and to elucidate the risk of second primary malignancies (SPMs), especially secondary hematologic malignancies (SHMs), attributable to RAI therapy.
View Article and Find Full Text PDF